1,5-二氟-2-硝基-4-三氟甲基苯 | 35010-29-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,5-二氟-2-硝基-4-三氟甲基苯
• 英文名称: 1,5-difluoro-2-nitro-4-trifluoromethylbenzene
• 英文别名: 2,4-Difluoro-5-nitrobenzotrifluoride；1,5-difluoro-2-nitro-4-(trifluoromethyl)benzene
• CAS: 35010-29-8
• 化学式: C₇H₂F₅NO₂
• 分子量: 227.09
• InChiKey: CRJRIPYSOOEORJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319

反应信息

• 作为反应物：
  描述：

  1,5-二氟-2-硝基-4-三氟甲基苯 在 5%-palladium/activated carbon 、 氢气 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 18.53h， 生成 1-amino-7-fluoro-6-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione
  参考文献：
  名称：

  N 1取代喹喔啉-2,3-二酮类作为海藻酸盐受体拮抗剂：X射线晶体学，结构亲和力关系和体外药理学

  摘要：

  在离子型谷氨酸受体中，人们对海藻酸酯受体的生理作用了解得较少。尽管可获得对海藻酸酯受体亚型GluK1具有选择性的配体，但对其余海藻酸酯受体亚型具有选择性的工具化合物稀疏。在这里，我们合成了一系列在N 1、6和7位具有取代基的喹喔啉-2,3-二酮，以研究GluK1-3和GluK5的结构-活性关系（SAR）。在天然和重组海藻酸盐和AMPA受体上的药理学表征表明，化合物37的GluK3结合亲和力（K i）为0.142μM，并且对GluK3的偏好是GluK3的8倍。尽管22对GluK3的结合亲和力较低（K i = 2.91μM），它对GluK3的偏好比对GluK1和GluK2的偏好高> 30倍。用GluK1配体结合结构域使化合物37结晶，以了解SAR。X射线结构显示37种蛋白以开放构象稳定了蛋白，这与拮抗剂结合模式一致。

  DOI：

  10.1021/acschemneuro.8b00726
• 作为产物：
  描述：

  2,4-二氟苯甲酸 在 硫酸 、 sulfur tetrafluoride 、 氢氟酸 、 硝酸 作用下， 生成 1,5-二氟-2-硝基-4-三氟甲基苯
  参考文献：
  名称：

  Synthesis and QSAR of Herbicidal 3-Pyrazolyl α,α,α-Trifluorotolyl Ethers

  摘要：

  Pyrazole nitrophenyl ethers (PPEs) were recently identified as a novel class of chemistry exerting herbicidal effects by inhibition of protoporphyrinogen IX oxidase. This area of chemistry has been extended to include herbicidal pyrazolyl fluorotolyl ethers. In these compounds, a trifluoromethyl group substitutes for the 4'-nitro group found in the original herbicides and in ''classical'' nitrodiphenyl ether hebicides. Fluoroanisole pyrazole ethers, in which a trifluoromethoxy group replaces the nitro group of diphenyl ether herbicides, are also described. The shift from 4'-nitro to 4'-trifluoromethyl substitution, which is conservative in terms of electrostatics, produced a novel class of herbicide with substantial pre-emergent activity on narrowleaf weed species. Quantitative structure/activity relationships obtained with respect to substitution on the pyrazole ring and at the 3'-position of the fluorotolyl moiety can be summarized effectively by comparative molecular field analysis. In general, 5-methanesulfonyl fluorotoluidide ethers were found to be most active.

  DOI：

  10.1021/jf9601978

文献信息

• 1,2,3,4-tetrahydroquinoxalinedione derivative
  申请人：Yamanouchi Pharmaceuticals Co., Ltd.

  公开号：US06096743A1

  公开（公告）日：2000-08-01

  A 1,2,3,4-tetrahydroquinoxalinedione derivative represented by the following formula (I) or salt thereof, an NMDA-glycine receptor and/or AMPA receptor antagonist or kainic acid neurotoxicity inhibitor containing the derivative or salt. In addition, a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier: ##STR1## wherein the substituents are as described in the specification.

  由以下公式（I）表示的1,2,3,4-四氢喹诺酮二酮衍生物或其盐，含有该衍生物或盐的NMDA-甘氨酸受体和/或AMPA受体拮抗剂或卡因酸神经毒性抑制剂。此外，包括所述化合物和药学上可接受的载体的药物组合物：##STR1##其中取代基如说明书中所述。
• A Facile Oxidation of Tertiary Amines to Lactams by Using Sodium Chlorite: Process Improvement by Precise pH Adjustment with CO2
  作者：Changhu Chu、Chaoyang Liu、Haozhou Sun、Cheng Qin、Tiannuo Yang、Wenxian Zhang、Yuan Zhou、Yani Li、Zheng Robert Jia

  DOI：10.1055/s-0040-1719920

  日期：2022.6

  By using cheap and innocuous sodium chlorite, a series of tertiary amines have been oxidized to the corresponding lactams with good selectivity and high yield. In this method, neither transition-metal catalyst nor oxidant was used. In the oxidation step, the pH of the sodium chlorite was precisely adjusted to pH around 6 using CO2, such pH is a compromise between oxidative properties, chemical stability

  通过使用廉价、无害的亚氯酸钠，一系列叔胺被氧化成相应的内酰胺，具有良好的选择性和高收率。在该方法中，既不使用过渡金属催化剂，也不使用氧化剂。在氧化步骤中，使用 CO 2将亚氯酸钠的 pH 值精确调节到 6 左右，这样的 pH 值是氧化特性、化学稳定性和不需要的沉淀之间的折衷。此外，缓冲盐不是必需的，这使得这种氧化反应可以在安全和环境友好的条件下进行。
• Imidazole-substituted quinoxalinedione derivatives
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06121264A1

  公开（公告）日：2000-09-19

  Imidazole-substituted quinoxalinedione derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions useful as glutamate receptor antagonists and the like, which comprise said compounds or salts thereof and pharmaceutically acceptable carriers. ##STR1## (Each symbol in the formula has the following meaning: A: a group represented by a formula (CH.sub.2).sub.m or a group represented by a formula Ph--(CH.sub.2).sub.p (Ph: a phenyl group), X: an oxygen atom or a group represented by a formula NR.sup.4, R.sup.1 : a hydrogen atom, a hydroxyl group or a triazolyl group, with the proviso that X may be a bond when R.sup.1 is a triazolyl group, R.sup.2 : a hydrogen atom, a nitro group, a halogeno-lower alkyl group, a cyano group, an amino group, a mono- or di-lower alkylamino group or a halogen atom, R.sup.3 and R.sup.4 : may be the same or different from each other and each represents a hydrogen atom or a lower alkyl group, n: 0, 1 or 2, m: an integer of 2 to 6, and p: an integer of 1 to 6.

  以下是通式（I）或其药学上可接受的盐的咪唑基取代喹噁啉二酮衍生物，并且包括这些化合物或其盐以及药学上可接受的载体的制药组合物，这些组合物对谷氨酸受体拮抗剂等具有用途。 ##STR1##（式中每个符号的含义如下：A：由公式（CH.sub.2）.sub.m表示的基团或由公式Ph--(CH.sub.2).sub.p（Ph：苯基）表示的基团，X：氧原子或由公式NR.sup.4表示的基团，R.sup.1：氢原子、羟基或三唑基，但若R.sup.1为三唑基，则X可以是键，R.sup.2：氢原子、硝基、卤代低烷基、氰基、氨基、单或双低烷基氨基或卤素原子，R.sup.3和R.sup.4：可以相同也可以不同，分别表示氢原子或低烷基，n：0、1或2，m：2到6的整数，p：1到6的整数。
• 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0784054A1

  公开（公告）日：1997-07-16

  A 1,2,3,4-tetrahydroquinoxalinedione derivative represented by the following formula (I) or salt thereof, an NMDA-glycine receptor and/or AMPA receptor antagonist or kainic acid neurotoxicity inhibitor containing the derivative or salt. In addition, a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier. wherein symbols in the above formula represent the following meanings, respectively: X: N, CH, R: an imidazolyl group or a di-lower alkylamino group, R1: (1) a halogen atom, a nitro group, a cyano group, a carboxyl group, an amino group, a mono- or di-lower alkylamino group, a lower alkanoyl group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group or a carbamoyl group, (2) a lower alkyl group or lower alkoxyl group which may be substituted by a halogen atom, a carboxyl group or an aryl group, (3) a phenyloxy group which may be substituted by a lower alkoxycarbonyl group or a carboxyl group, R2: a hydroxyl group, a lower alkoxyl group, an amino group or a mono- or di-lower alkylamino group, A: a lower alkylene group which may be substituted or a group represented by the formula -O-B-, and B: a lower alkylene group,    with the proviso that the case wherein R represents an imidazolyl group, R1 represents a cyano group, A represents an ethylene group and R2 represents a hydroxyl group is excluded.

  一种由下式（I）代表的 1，2，3，4-四氢喹喔啉二酮衍生物或其盐，一种含有该衍生物或盐的 NMDA-甘氨酸受体和/或 AMPA 受体拮抗剂或凯尼酸神经毒性抑制剂。此外，还包括上述化合物和药学上可接受的载体的药物组合物。 其中，上式中的符号分别代表以下含义： X：N，CH、 R：咪唑基团或二低级烷基氨基、 R1: (1) 卤素原子、硝基、氰基、羧基、氨基、单或双低级烷基氨基、低级烷酰基、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基或氨基甲酰基、 (2) 可被卤素原子、羧基或芳基取代的低级烷基或低级烷氧基、 (3) 可被低级烷氧基羰基或羧基取代的苯氧基、 R2：羟基、低级烷氧基、氨基或单或双低级烷基氨基、 A：可被取代的低级亚烷基或由式-O-B-代表的基团，以及 B：低级亚烷基、 但 R 代表咪唑基、R1 代表氰基、A 代表乙烯基和 R2 代表羟基的情况除外。
• IMIDAZOLE-SUBSTITUTED QUINOXALINEDIONE DERIVATIVES
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0919554A1

  公开（公告）日：1999-06-02

  Imidazole-substituted quinoxalinedione derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions useful as glutamate receptor antagonists and the like, which comprise said compounds or salts thereof and pharmaceutically acceptable carriers. (Each symbol in the formula has the following meaning: A: a group represented by a formula (CH2)m or a group represented by a formula Ph-(CH2)p (Ph: a phenyl group), X: an oxygen atom or a group represented by a formula NR4, R1: a hydrogen atom, a hydroxyl group or a triazolyl group, with the proviso that X may be a bond when R1 is a triazolyl group, R2: a hydrogen atom, a nitro group, a halogeno-lower alkyl group, a cyano group, an amino group, a mono- or di-lower alkylamino group or a halogen atom, R3 and R4: may be the same or different from each other and each represents a hydrogen atom or a lower alkyl group, n: 0, 1 or 2, m: an integer of 2 to 6, and p: an integer of 1 to 6.)

  由以下通式(I)代表的咪唑取代的喹喔啉二酮衍生物或其药学上可接受的盐，以及可用作谷氨酸受体拮抗剂等的药物组合物，其中包含所述化合物或其盐和药学上可接受的载体。 (式中各符号含义如下： A：由式 (CH2)m 代表的基团或由式 Ph-(CH2)p 代表的基团（Ph：苯基）、 X：氧原子或由式 NR4 代表的基团、 R1：氢原子、羟基或三唑基，但当 R1 为三唑基时，X 可以是键、 R2：氢原子、硝基、卤素-低级烷基、氰基、氨基、单-或双-低级烷基氨基或卤素原子、 R3 和 R4：可以相同或互不相同，各自代表一个氢原子或一个低级烷基、 n:0、1 或 2、 m：2 至 6 的整数，以及 p：1 至 6 的整数）。